Affymax (AFFY) says Takeda Pharmaceuticals (TKPYY.PK) will not commercialize peginesatide, an...

|By:, SA News Editor

Affymax (AFFY) says Takeda Pharmaceuticals (TKPYY.PK) will not commercialize peginesatide, an investigational therapy for treating patients with anemia due to chronic kidney disease, in Japan. Takeda said commercialization in the area was "not strategically optimal." The companies will continue to collaborate in developing the drug for commericalization outside Japan, including preparing to file for regulatory approvals in the U.S. and Europe. Shares -6.5% AH.